HC Wainwright Reiterates Buy Rating for Valneva (NASDAQ:VALN)

Valneva (NASDAQ:VALN)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a research report issued on Friday,Benzinga reports. They currently have a $17.00 price target on the stock. HC Wainwright’s target price would suggest a potential upside of 134.48% from the company’s current price.

Valneva Stock Performance

Shares of NASDAQ:VALN opened at $7.25 on Friday. The business’s 50-day simple moving average is $6.29 and its 200 day simple moving average is $5.61. Valneva has a one year low of $3.62 and a one year high of $9.50. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.25 and a current ratio of 2.78. The company has a market cap of $589.14 million, a P/E ratio of -55.77 and a beta of 1.93.

Valneva (NASDAQ:VALN) last posted its quarterly earnings data on Wednesday, March 19th. The company reported ($0.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.32). Valneva had a negative net margin of 4.35% and a negative return on equity of 3.93%. On average, sell-side analysts forecast that Valneva will post 0.13 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Valneva stock. Wells Fargo & Company MN lifted its position in shares of Valneva SE (NASDAQ:VALN) by 14.3% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 246,766 shares of the company’s stock after acquiring an additional 30,859 shares during the period. Wells Fargo & Company MN owned 0.30% of Valneva worth $1,079,000 as of its most recent filing with the SEC. 11.39% of the stock is owned by institutional investors.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.